Search | Page 7 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes

    ... Journal Title:  J Blood Med Primary Author:  ... of patients with del(5q) MDS, including reduction in red blood cell transfusion requirements and improvements in quality of ...

    Research Article last updated 03/02/2015 - 2:11pm.

  2. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab

    ... Journal Title:  Blood Primary Author:  ... During the study, six patients received at least one red blood cell transfusion . Lack of detectable CH50 activity (defined by ...

    Research Article last updated 01/20/2015 - 2:28pm.

  3. The Effect of Decitabine Dose Modification and Myelosuppression on Response and Survival in Patients With Myelodysplastic Syndromes

    ... patients with MDS conducted Cox regression analyses of red blood cell or platelet dependence, myelosuppression, dose ...

    Research Article last updated 06/02/2014 - 11:03am.

  4. Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults

    ... to Medicare claims. Baseline characteristics, treatment ( red blood cell transfusions, hematopoietic growth factors, hypomethylating ...

    Research Article last updated 11/19/2012 - 2:37pm.

  5. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

    ... Journal Title:  Blood Primary Author:  ... cytogenetics , presence of circulating blasts, and red blood cell transfusion dependency ≥ 4 units/8 weeks (all P < 10(-4)) ...

    Research Article last updated 07/28/2014 - 8:53am.

  6. Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502) (CHAMP)

    ... phase II study with one arm receiving unrelated cord blood transplantation and the other arm receiving haploidentical ... separately in the 2 arms at 1 year post-hematopoietic stem cell transplantation (HSCT). ... of 4.0 x10^7/kg (sum of unit 1 and unit 2). For non- red blood cell depleted units, the minimum pre-cryopreserved TNC dose is ...

    Clinical Trial last updated 12/19/2017 - 7:55am.

  7. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: A clinical practice guideline.

    ... expected with the aging population. Treatment includes red blood cell transfusion for anemia . The immunomodulatory agents ...

    Research Article last updated 10/01/2012 - 10:04am.

  8. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes

    ... risks associated with transfusions, chronic anemia and red blood cell (RBC) transfusion dependence impact negatively on survival and ...

    Research Article last updated 06/15/2012 - 2:03pm.

  9. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.

    ... 24 and 52 weeks of therapy despite ongoing receipt of red blood cell transfusions. ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Myelodysplastic syndromes and the role of iron overload.

    ... in patients with MDS due to the long-term use of red blood cell transfusions in patients with symptomatic anemia . ...

    Research Article last updated 10/11/2011 - 5:58pm.